DK1408976T3 - Behandling af ADHD (Attention deficit hyperactivity disorder) - Google Patents

Behandling af ADHD (Attention deficit hyperactivity disorder)

Info

Publication number
DK1408976T3
DK1408976T3 DK02756536T DK02756536T DK1408976T3 DK 1408976 T3 DK1408976 T3 DK 1408976T3 DK 02756536 T DK02756536 T DK 02756536T DK 02756536 T DK02756536 T DK 02756536T DK 1408976 T3 DK1408976 T3 DK 1408976T3
Authority
DK
Denmark
Prior art keywords
adhd
attention deficit
hyperactivity disorder
treatment
deficit hyperactivity
Prior art date
Application number
DK02756536T
Other languages
English (en)
Other versions
DK1408976T5 (da
Inventor
Daniel W Goodman
Daniela Brunner
Original Assignee
Psychogenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Psychogenics Inc filed Critical Psychogenics Inc
Publication of DK1408976T3 publication Critical patent/DK1408976T3/da
Application granted granted Critical
Publication of DK1408976T5 publication Critical patent/DK1408976T5/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK02756536.5T 2001-07-20 2002-07-19 Behandling af ADHD (Attention deficit hyperactivity disorder) DK1408976T5 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30682501P 2001-07-20 2001-07-20
US38293102P 2002-05-23 2002-05-23
PCT/US2002/023081 WO2003007956A1 (en) 2001-07-20 2002-07-19 Treatment for attention-deficit hyperactivity disorder

Publications (2)

Publication Number Publication Date
DK1408976T3 true DK1408976T3 (da) 2009-06-29
DK1408976T5 DK1408976T5 (da) 2011-01-10

Family

ID=26975388

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02756536.5T DK1408976T5 (da) 2001-07-20 2002-07-19 Behandling af ADHD (Attention deficit hyperactivity disorder)

Country Status (11)

Country Link
US (5) US7504395B2 (da)
EP (2) EP1408976B3 (da)
JP (1) JP5080716B2 (da)
AT (1) ATE424825T1 (da)
AU (2) AU2002322539B2 (da)
CA (1) CA2453837C (da)
DE (1) DE60231507D1 (da)
DK (1) DK1408976T5 (da)
ES (1) ES2323451T7 (da)
HK (1) HK1065478A1 (da)
WO (1) WO2003007956A1 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048906B2 (en) * 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
ES2323451T7 (es) * 2001-07-20 2011-08-01 Psychogenics Inc. Tratamiento para el trastorno de hiperactividad con deficit de atencion.
US8134029B2 (en) 2002-09-16 2012-03-13 Sunovion Pharmaceuticals Inc. Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine
US8751031B2 (en) * 2004-02-06 2014-06-10 Zircore, Llc System and method for mass custom manufacturing of dental crowns and crown components
MX2008000250A (es) 2005-07-06 2008-03-19 Sepracor Inc Combinaciones de eszopiclona y trans-4-(3,4-diclorofenil)-1,2,3,4- tetrahidro-n-metil-1-naftalenamina o trans 4-(3,4-diclorofenil)-1, 2,3,4-tetrahidro-1-naftalenamina y metodos de tratamiento de menopausia y trastornos del estado de animo, ansiedad y
US9066903B2 (en) 2006-02-28 2015-06-30 The United States Of America As Represented By The Department Of Veterans Affairs Pharmacological treatment of Parkinson's disease
CN103054868B (zh) * 2008-05-30 2016-08-31 赛科基因股份有限公司 用于神经和精神障碍的治疗
CA2759180A1 (en) * 2009-05-13 2010-11-18 Sunovion Pharmaceuticals Inc. Compositions comprising transnorsertraline and serotonin receptor 1a agonists/antagonists and uses thereof
MX2011013775A (es) * 2009-06-25 2012-04-20 Alcobra Ltd Un metodo para el tratamiento, alivio de sitomas de, mitigacion, mejoramieto y prevencion de una enfermedad, desorden o condicion cognoscitiva.
WO2011000562A1 (en) 2009-06-30 2011-01-06 Merz Pharma Gmbh & Co. Kgaa Eltoprazine for the treatment of certain movement disorders
WO2011000564A1 (en) 2009-06-30 2011-01-06 Merz Pharma Gmbh & Co. Kgaa Eltoprazine for the treatment of drug addiction
US20120190690A1 (en) 2009-06-30 2012-07-26 Merz Pharma Gmbh & Co. Kgaa Eltoprazine for the treatment of weight disorders
US20120136005A1 (en) 2009-06-30 2012-05-31 Merz Pharma Gmbh & Co. Kgaa Eltoprazine for the treatment of anxiety
US8894415B2 (en) * 2009-09-29 2014-11-25 Advanced Training System Llc System, method and apparatus for driver training
WO2014180556A1 (en) * 2013-05-06 2014-11-13 Merz Pharma Gmbh & Co. Kgaa Arylpiperazines
JP7406285B1 (ja) 2023-03-09 2023-12-27 国立大学法人島根大学 ビリルビン誘発性神経機能障害、黄疸を伴う精神疾患、又はビリルビンｕｄｐ－グルクロン酸転移酵素遺伝子変異に起因する精神疾患を治療、予防又は管理するための医薬組成物

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4039653A (en) * 1974-01-23 1977-08-02 Defoney, Brenman, Mayes & Baron Long-acting articles for oral delivery and process
CH653021A5 (fr) 1981-04-24 1985-12-13 Delalande Sa Derives piperidino, piperazino et homopiperazino, n-substitues par un groupe heterocyclique aromatique, leur procede de preparation et composition therapeutique les contenant.
FR2524312B1 (fr) * 1982-04-01 1985-10-04 Tech Cuir Centre Nouvelles formes de micro-encapsulation de substances medicamenteuses par des couches homogenes de collagene natif
AU577802B2 (en) 1983-10-17 1988-10-06 Duphar International Research B.V. Blood-pressure lowering piperazine derivatives
EP0190472B1 (en) 1984-12-21 1989-07-12 Duphar International Research B.V New pharmaceutical compositions having anti-psychotic properties
ATE81975T1 (de) 1984-12-21 1992-11-15 Duphar Int Res Arzneimittel mit psychotroper wirkung.
GB8521494D0 (en) * 1985-08-29 1985-10-02 Zyma Sa Controlled release tablet
US4797286A (en) * 1985-11-12 1989-01-10 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulations
CA1279645C (en) 1986-02-27 1991-01-29 Ineke Van Wijngaarden Aryl-substituted (n-piperidinyl)methyl- and (n-piperazinyl)methylazoles having antipsychotic properties
GB8613689D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
MX173362B (es) 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
DK172628B1 (da) 1987-09-11 1999-08-02 Duphar Int Res Anvendelse af piperazinderivater til fremstilling af lægemidler til behandling af syndromer, der involverer frygt eller fry
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
DK611489A (da) 1988-12-08 1990-06-09 Duphar Int Res Anxiolytisk aktive piperazinderivater og farmaceutiske praeparater med indhold af saadanne forbindelser
GB8830312D0 (en) 1988-12-28 1989-02-22 Lundbeck & Co As H Heterocyclic compounds
SE8904361D0 (sv) 1989-12-22 1989-12-22 Astra Ab New chroman and thiochroman derivatives
FR2670491B1 (fr) 1990-12-14 1993-02-05 Adir Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les renfermant.
MX9201991A (es) 1991-05-02 1992-11-01 Jonh Wyeth & Brother Limited Derivados de piperazina y procedimiento para su preparacion.
IT1251144B (it) 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone
GB9125900D0 (en) 1991-12-05 1992-02-05 Wyeth John & Brother Ltd Piperazine derivatives
EP0556889A1 (en) 1992-02-18 1993-08-25 Duphar International Research B.V Method of preparing aryl(homo)piperazines
FR2692264B1 (fr) 1992-06-12 1994-08-05 Adir Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les contenant.
DK148392D0 (da) 1992-12-09 1992-12-09 Lundbeck & Co As H Heterocykliske forbindelser
DE69325698T2 (de) 1992-12-21 2000-01-27 Duphar Int Res Enzymatisches Verfahren zur stereoselektiven Herstellung einem Enantiomer aus einem hetero bicyclischen Alkohols
RU2118322C1 (ru) 1993-07-05 1998-08-27 Дюфар Интернэшнл Рисерч Б.В. 2,3-дигидро-1,4-бензодиокси-5-ил-пиперазиновые производные или их соли
WO1995003801A1 (fr) * 1993-07-28 1995-02-09 Nippon Shinyaku Co., Ltd. Antidepressif
WO1995011243A1 (en) 1993-10-19 1995-04-27 Smithkline Beecham Plc Benzanilide derivatives as 5ht-1d receptor antagonists
EP0650964A1 (en) 1993-11-02 1995-05-03 Duphar International Research B.V 1 2H-1-benzopyran-2-one-8-yl -piperazine derivatives
IL112764A0 (en) 1994-03-18 1995-05-26 Ferrer Int New chromene derivatives
MX9700080A (es) 1994-06-29 1997-04-30 Pfizer Derivados de aril y heteroaril alcoxinaftaleno.
FR2725623A1 (fr) * 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
EP0710481A1 (en) 1994-11-02 1996-05-08 Duphar International Research B.V Use of flesinoxan for cognition enhancement
JPH10510253A (ja) 1994-12-07 1998-10-06 ビイク グルデン ロンベルク ヒェーミッシェ ファブリーク ゲゼルシャフト ミット ベシュレンクテル ハフツング ウラシル誘導体
US5741789A (en) * 1995-01-17 1998-04-21 Eli Lilly And Company Compounds having effects on serotonin-related systems
US6114334A (en) 1995-07-13 2000-09-05 Knoll Aktiengesellschaft Piperazine derivatives as therapeutic agents
GB9514901D0 (en) 1995-07-20 1995-09-20 American Home Prod Piperazine derivatives
SE9601110D0 (sv) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
CZ294413B6 (cs) 1996-03-29 2004-12-15 Duphar International Research B. V. Piperazinová nebo piperidinová sloučenina, způsob její přípravy, farmaceutický prostředek tuto sloučeninu obsahující a použití této sloučeniny pro přípravu farmaceutického přípravku
US5846982A (en) * 1996-06-14 1998-12-08 Eli Lilly And Company Inhibition of serotonin reuptake
DK0932609T3 (da) 1996-10-15 2003-09-01 Wyeth Corp Azaheterocyclomethylderivater af 2,3,8,9-tetrahydro-7H-1,4-dioxino[2,3-e]indol-8-on
FR2760014B1 (fr) 1997-02-27 1999-04-09 Adir Nouveaux composes de 2-amino indane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB9706089D0 (en) * 1997-03-24 1997-05-14 Scherer Ltd R P Pharmaceutical composition
DE19730989A1 (de) * 1997-07-18 1999-01-21 Merck Patent Gmbh Piperazin-Derivate
WO1999005140A1 (en) 1997-07-25 1999-02-04 H. Lundbeck A/S Indole and 2,3-dihydroindole derivatives, their preparation and use
US5942244A (en) * 1997-07-31 1999-08-24 Farmo-Nat Ltd. Local oral herbal slow release tablets
ATE253058T1 (de) 1997-09-02 2003-11-15 Duphar Int Res Piperidin- und piperazin derivate als 5-ht1- rezeptor-agonisten
SE9703374D0 (sv) * 1997-09-18 1997-09-18 Astra Ab A new combination
SE9703375D0 (sv) * 1997-09-18 1997-09-18 Astra Ab A new combination
SE9703378D0 (sv) * 1997-09-18 1997-09-18 Astra Ab New compounds
SE9703376D0 (sv) * 1997-09-18 1997-09-18 Astra Ab A new combination
TW530054B (en) 1997-09-24 2003-05-01 Duphar Int Res New piperazine and piperidine compounds
FR2769312B1 (fr) 1997-10-03 1999-12-03 Adir Nouveaux composes de l'indanol, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
IL127497A (en) 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US6310066B1 (en) 1998-04-29 2001-10-30 American Home Products Corp. Antipsychotic indolyl derivatives
US6387904B2 (en) 1998-05-18 2002-05-14 Pfizer Inc Method of treating glaucoma and ischemic retinopathy
EP0985414B1 (en) 1998-05-26 2003-08-27 Pfizer Products Inc. Medicament for the treatment of glaucoma and ischemic retinopathy
GB9812523D0 (en) 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
US6376494B1 (en) 1998-06-15 2002-04-23 American Home Products Corporation Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents
US6242448B1 (en) 1998-12-17 2001-06-05 American Home Products Corporation Trisubstituted-oxazole derivatives as serotonin ligands
US6313126B1 (en) 1999-01-07 2001-11-06 American Home Products Corp Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression
AR022303A1 (es) 1999-01-22 2002-09-04 Lundbeck & Co As H Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion
US6306859B1 (en) 1999-03-02 2001-10-23 American Home Products Corporation N-substituted imide derivatives with serotonergic activity
ES2162731B1 (es) 1999-06-04 2003-02-16 Faes Fabrica Espanola De Produ Nuevas arilpiperacilnilalquil-3(2h)-piridacinonas.
DK1204654T3 (da) * 1999-07-29 2003-11-17 Lilly Co Eli Benzofurylpiperaziner og benzofurylhomopiperaziner: Serotonin agonister
ATE239722T1 (de) 1999-07-29 2003-05-15 Lilly Co Eli Benzofurylpiperazine als serotonin-agonisten
AR027133A1 (es) 1999-12-30 2003-03-12 Lundbeck & Co As H Derivados de heteroarilo, su preparacion y uso.
DZ3370A1 (fr) 2000-05-12 2001-11-15 Solvay Pharm Bv Composes de piperazine et piperidine
CA2405758A1 (en) 2000-05-12 2001-11-15 Solvay Pharmaceuticals B.V. Use of compounds having combined dopamine d2, 5-ht1a and alpha adrenoreceptor agonistic action for treating cns disorders
US20020016334A1 (en) 2000-07-31 2002-02-07 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD)
DE10041574A1 (de) 2000-08-24 2002-03-07 Merck Patent Gmbh Chromenonderivate
DE10043659A1 (de) 2000-09-05 2002-03-14 Merck Patent Gmbh Arylpiperazinderivate
US7034029B2 (en) * 2000-11-02 2006-04-25 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
EP2298738B1 (en) * 2000-11-02 2012-09-19 Wyeth LLC 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
US6469007B2 (en) 2000-11-28 2002-10-22 Wyeth Serotonergic agents
ES2188344B1 (es) 2000-11-29 2004-09-16 Laboratorios Vita, S.A. Compuestos derivados de benzotiofeno, su procedimiento de obtencion y utilizacion de los mismos.
AR032711A1 (es) 2001-02-21 2003-11-19 Solvay Pharm Bv Derivados de fenilpiperazina, un metodo para la preparacion de los mismos y una composicion farmaceutica que los contiene
SK652004A3 (en) 2001-06-29 2004-09-08 Lundbeck & Co As H Heteroaryl derivatives, pharmaceutical composition with the content thereof and use of the same
ES2323451T7 (es) * 2001-07-20 2011-08-01 Psychogenics Inc. Tratamiento para el trastorno de hiperactividad con deficit de atencion.
HU227237B1 (en) 2001-09-27 2010-12-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Substituted alkylpyridazinone derivatives, process for their preparation, pharmaceutical compositions containing them
ITMI20012060A1 (it) 2001-10-05 2003-04-05 Recordati Chem Pharm Nuovi eterocilcli n-acilati
EP1336406A1 (en) 2002-02-14 2003-08-20 Solvay Pharmaceuticals B.V. Partial dopamine-D2 receptor agonist plus serotonin and/or noradrenaline inhibitory activity
EP1483256A2 (en) 2002-03-12 2004-12-08 Wyeth Process for making chiral 1,4-disubstituted piperazines
IL163829A0 (en) 2002-03-12 2005-12-18 Wyeth Corp Preparation of N1-(2'-pyridyl)-1,2-propanediamine sulfamic acid and its use in the synthesis of biologically active piperazines
CA2477892C (en) 2002-03-12 2010-11-23 Gregg Brian Feigelson Process for synthesizing chiral n-aryl piperazines
MXPA04011254A (es) 2002-05-13 2005-01-25 Hoffmann La Roche Derivados de benzoxazina como moduladores de 5-hidroxitriptamina 6 (5-ht6) y usos de los mismos.
US20040072839A1 (en) 2002-06-14 2004-04-15 Amedeo Leonardi 1-Phenylalkylpiperazines
US20040002500A1 (en) 2002-06-28 2004-01-01 Fabre Kramer Pharmaceutical, Inc. Methods for treating attention deficit disorder
US7067518B2 (en) 2002-09-05 2006-06-27 Wyeth Pyridinyl-methyl-ethyl cyclohexanecarboxamides as serotonergic agents
US7153849B2 (en) 2002-09-12 2006-12-26 Wyeth Antidepressant arylpiperazine derivatives of hetrocycle-fused benzodioxans
DK1562918T3 (da) 2002-11-08 2008-05-05 Hoffmann La Roche Substituerede benzoxazinoner og anvendelser deraf
US20040147581A1 (en) 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
US20050004105A1 (en) 2003-01-29 2005-01-06 Emer Leahy Treatment for a attention-deficit hyperactivity disorder
DE602004010791T2 (de) 2003-03-03 2008-12-04 F. Hoffmann-La Roche Ag 2,5-substituiertetetrahydroisochinoline zur verwendung als 5-ht6 modulatoren
MXPA05012391A (es) 2003-05-16 2006-02-02 Pfizer Prod Inc Tratamiento de trastornos psicoticos y depresivos.
KR20060009938A (ko) 2003-05-16 2006-02-01 화이자 프로덕츠 인코포레이티드 양극성 장애 및 연관된 증상의 치료
MXPA05012325A (es) 2003-05-16 2006-01-30 Pfizer Prod Inc Procedimiento para potenciar la cognicion usando zipirasidona.
CA2525868A1 (en) 2003-05-16 2004-11-25 Pfizer Products Inc. Anxiety treatments with ziprasidone
US20050065158A1 (en) 2003-07-16 2005-03-24 Pfizer Inc. Treatment of sexual dysfunction
US7435738B2 (en) 2003-08-18 2008-10-14 Solvay Pharmaceuticals, Inc. Stable crystalline form of bifeprunox mesylate (7-[4-([1,1′-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate)
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
ES2291984T3 (es) 2003-12-09 2008-03-01 F. Hoffmann-La Roche Ag Derivados de benzoxazina y su empleo.

Also Published As

Publication number Publication date
US20060004023A1 (en) 2006-01-05
US20090104261A1 (en) 2009-04-23
WO2003007956A1 (en) 2003-01-30
ES2323451T7 (es) 2011-08-01
JP5080716B2 (ja) 2012-11-21
US20110008425A1 (en) 2011-01-13
US7557109B2 (en) 2009-07-07
ES2323451T3 (es) 2009-07-16
AU2007254677B2 (en) 2009-11-12
ATE424825T1 (de) 2009-03-15
US7504395B2 (en) 2009-03-17
HK1065478A1 (en) 2005-02-25
EP1408976B1 (en) 2009-03-11
AU2007254677A1 (en) 2008-01-24
EP1408976A4 (en) 2007-05-16
JP2004538282A (ja) 2004-12-24
AU2002322539B2 (en) 2007-09-27
EP2036547A3 (en) 2009-12-23
DE60231507D1 (de) 2010-07-01
EP2036547A2 (en) 2009-03-18
EP1408976B3 (en) 2010-08-25
CA2453837A1 (en) 2003-01-30
CA2453837C (en) 2011-10-04
US20120070494A1 (en) 2012-03-22
US20030050308A1 (en) 2003-03-13
DK1408976T5 (da) 2011-01-10
EP1408976A1 (en) 2004-04-21

Similar Documents

Publication Publication Date Title
DK1408976T3 (da) Behandling af ADHD (Attention deficit hyperactivity disorder)
ATE415968T1 (de) 3,11b-cis-dihydrotetrabanezin zur behandlung von schizophrenie und anderen psychosen
ATE296634T1 (de) (s,s)-reboxetin zur behandlung von fibromyalgie und anderen somatoformen störungen
ATE542801T1 (de) Zur behandlung von neoplastischen krankheiten, entzündlichen erkrankungen und erkrankungen des immunsystems geeignete 2,4-pyrimidindiamine
HK1087351A1 (en) Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit
ATE481093T1 (de) Vervendung von dexrazoxane in der prävention und behandlung der alzeheimer-krankheit
BR0309665A (pt) Tratamento de deficiência de alfa-galactosidase a
NO20053185D0 (no) Behandling av oppmerksomhetssviktshyperaktivitetsforstyrrelse.
ATE410430T1 (de) 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
CY1107911T1 (el) Διαταξη αφαιρεσεως
ATE316787T1 (de) Kombination von fenofibrat und von coenzym q10 für die behandlung der endotheliaal missfunktion
CY1109238T1 (el) Δισκιο περιεχον σετιριζινη και ψευδοεφεδρινη
BRPI0418589A (pt) composições farmacêuticas e métodos para tratamento por insulina
ATE319439T1 (de) Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd
DK1491212T3 (da) Middel til behandling af søvnforstyrrelser
ATE357438T1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
ATE400564T1 (de) Ppar alpha selektive verbindungen zur behandlung von dyslipidämie und anderen lipidstörungen
NL1021504A1 (nl) Waterstofbehandelingsproces.
ATE494307T1 (de) Neoplasma-spezifische antikörper und deren verwendungen
ATE443262T1 (de) Molekulardiagnoseverfahren und behandlung von demenz mit lewy-körperchen
DK1530462T3 (da) 1-phenyl-2-dimethylaminomethylcyclohexanforbindelser til behandling af depressionssymtomer. smerte og inkontinens
DE50300918D1 (de) Anlage zum sterilisieren, pasteurisieren und/oder desinfizieren pump- oder rieselfaehiger medien
DK1523985T3 (da) Ikke-radioaktivt strontiumholdigt middel til behandling af kræft
DE60215219D1 (de) Verwendung von darifenacin zur behandlung des harndrangs
DE60227078D1 (de) Allylmercaptocaptoprilverbindungen und deren verwendungen